Announced

Completed

Agilent Technologies completed the acquisition of BIOVECTRA for $925m.

Synopsis

Agilent Technologies, an analytical and clinical laboratory technologies firm, completed the acquisition of BIOVECTRA, a global biotech and pharmaceutical company, for $925m. “We are delighted to officially welcome the BIOVECTRA team to Agilent. This acquisition demonstrates our commitment to providing customers the most advanced capabilities to accelerate their therapeutics programs, including best-in-class cGMP pharmaceutical manufacturing,” Padraig McDonnell, Agilent President and CEO.

Show Details & Financials

Did you work on this deal?

Showcase your expertise to over 3 million dealmakers and industry leaders on Datasite.

© COPYRIGHT 2024 MERGERLINKS LIMITED.

ALL RIGHTS RESERVED.

15 BONHILL STREET, LONDON, EC2A 4DN, UNITED KINGDOM.

CONTACT US